# Psychedelic Microdosing and Mental Health

Low-dose LSD has real measurable effects, but sustained depression/anxiety relief from repeated microdosing remains unconfirmed beyond expectancy and concurrent care.

Primary-subclaim aggregation returns SC2 Γ. Controlled acute drug action and direct exploratory MDD improvement provide partial support, while a now verified masked clinical conference report is primary-null. Neither healthy nulls nor a single imprecise conference result establish universal inefficacy, and the open-label positive cannot override the clinical comparator. Full-dose and ketamine results retain their actual scopes.

Tested acute, healthy, ADHD, psilocybin and clinical MDD comparator findings are explicitly scoped. The clinical masked conference null does not imply that no person or untested regimen could benefit. No verified positive context-specific MDD microdose causal effect is mapped across adults. Full-dose and ketamine clinical experiments are separate.